Edition:
United States

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.20EUR
14 Dec 2017
Change (% chg)

€-0.01 (-0.50%)
Prev Close
€1.21
Open
€1.21
Day's High
€1.22
Day's Low
€1.19
Volume
9,342,057
Avg. Vol
30,747,314
52-wk High
€1.38
52-wk Low
€0.22

Summary

Name Age Since Current Position

Paul Sekhri

59 2016 Chairman of the Board of Supervisory Directors

Sijmen de Vries

58 2008 Member of the Management Board, Chief Executive Officer

Juergen Ernst

78 2011 Vice Chairman of the Board of Supervisory Directors

Robin Wright

53 2015 Chief Financial Officer, Member of the Management Board

Bruno Giannetti

65 2006 Member of the Management Board, Chief Operations Officer

Anne-Marie de Groot

Senior Vice President Organizational Development, Member of the Management Board

Jaap Blaak

76 2016 Member of the Board of Supervisory Directors

Aad de Winter

64 2009 Member of the Board of Supervisory Directors

Jan Egberts

58 2015 Member of the Board of Supervisory Directors

Jonh Ward

76 2007 Member of the Board of Supervisory Directors

Biographies

Name Description

Paul Sekhri

Mr. Paul J. Sekhri has served as Chairman of the Board of Supervisory Directors of Pharming Group NV since May 25, 2016. He has been Member of the Board of Supervisory Directors of the Company since April 30, 2015. He has over 28 years of operational experience in life sciences with in-depth knowledge of multinational pharmaceutical and biotechnology markets and products. Mr. Sekhri is currently Chief Executive Officer of Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, where he led the creation of innovative solutions and business models to meet patient needs. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries Ltd. Mr. Sekhri has held positions in small biopharmaceutical companies, large and small pharmaceutical companies, and venture capital/private equity firms, including TPG, Cerimon Pharmaceuticals, Ariad Pharmaceuticals and Novartis AG. Mr. Sekhri completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine and received his BSc degree from the University of Maryland.

Sijmen de Vries

Dr. Sijmen de Vries has been Member of the Management Board, Chief Executive Officer of Pharming Group NV since October 13, 2008. He has extensive senior level experience in both the pharmaceutical and biotechnology industry. He joined Pharming from Switzerland-based 4-Antibody where he was CEO. Dr. de Vries has also been CEO of Morphochem AG and prior to this he worked at Novartis Pharma and Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc where he held senior business and commercial positions. Dr. de Vries holds an MD degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).

Juergen Ernst

Mr. Juergen H. L. Ernst has served as Vice Chairman of the Board of Supervisory Directors at the Pharming Group NV since 2011. Previously, he was Member of the Board of Supervisory Directors from April 15, 2009. He has experience in the field of pharmaceutical development and marketing. From 1969 until 1989, he held several positions at Kali-Chemie AG (subsidiary of Solvay SA), including Head of Pharmaceutical Marketing and Head of Pharmaceutical Division. In 1989, Mr. Ernst continued his career at Solvay and held several positions until he retired in 2004. Amongst other, he was member of the board of Pharmaceutical Division, CEO of Health Divisions, General Manager Pharmaceutical Sector and supervisory director and member of the Executive Committee. Mr. Ernst holds an ISMP Degree from Harvard University and an MBA from the University of Cologne. He is member of the Audit and Remuneration Committee of the Company.

Robin Wright

Mr. Robin Wright has been Chief Financial Officer and Member of the Management Board of Pharming Group N.V. since October 28, 2015. He has senior level experience as a CFO of public companies in both the pharmaceutical and biotechnology industries. He is a qualified accountant and joins Pharming from Sweden-based Karolinska Development AB, where he was CFO and Head of Business Development. Mr. Wright was also CFO and Head of Business Development at Orexo AB in Sweden. Prior to this, he worked in private equity and corporate finance advisory roles, including long periods at Citibank Salomon Smith Barney and Barclays de Zoete Wedd. He has completed over 165 global license and M&A transactions as well as many financing transactions within the pharma/biotech sector. Mr. Wright holds a BA degree in chemistry from Oxford University and is a Fellow of the Institute of Chartered Accountants in England and Wales in the UK.

Bruno Giannetti

Dr. Bruno M. Giannetti has been Member of the Management Board, Chief Operations Officer of Pharming Group NV since December 1, 2006. He has more than 30 years of experience in the pharmaceutical and biotech industry. Previously, he was the CEO of AM-Pharma BV (NL) and President and CEO of Verigen AG, Germany. He has served as senior management consultant for pharmaceutical R&D projects at Coopers & Lybrand (in Switzerland and the UK). Dr. Giannetti was also worldwide Vice-President Marketing and Medical Information at Immuno, Austria and Head of Clinical Research at Madaus AG, Germany. Dr. Giannetti holds a PhD in Chemistry, a MD PhD degree in Medicine from the University of Bonn and has recently been appointed Professor at the Pharmaceutical Faculty of the University of Seville (Spain).

Anne-Marie de Groot

Mrs. Anne-Marie de Groot serves as Senior Vice President Organizational Development and Member of the Management Board of Pharming Group NV. She has experience leading the Human Resources, Internal Communications, Information Technologies and Support Services groups and plays a key role in aligning talent to business strategy, cultivating an environment of high employee engagement and in developing the organizational design. Mrs. de Groot has over 10 years of experience crossing the full spectrum of the HR discipline including leadership and talent development, talent acquisition, corporate culture development, organization design and restructuring, mergers and acquisitions, compensation and benefits, payroll and performance management. She held various Human Resources and Talent Acquisition positions at Randstad, Janssen Pharmaceuticals (the pharmaceutical companies of Johnson and Johnson) and Pharming. She holds a Bachelor in Social Work and a Bachelor in Human Resources Management from Hogeschool Leiden.

Jaap Blaak

Mr. Jaap Blaak has been Member of the Board of Supervisory Directors of Pharming Group NV since May 23, 2007. He was Chairman of the Board of Supervisory Directors at Pharming Group NV from 2008 until May 25, 2016. He has held managerial positions with Hoogovens and Indivers NV and Interturbine Holding BV in the Netherlands, USA, Germany and Singapore. In 1983, he was involved with the foundation of the MIP Equity Fund, one of the largest venture capital groups in Europe, and was appointed CEO in 1986. MIP merged with the ABN-AMRO Venture Capital Group to form AlpInvest. Mr. Blaak has been an advisor to the Dutch Ministry of Economic Affairs for the Biopartner and Technopartner Program and other innovative projects related to Entrepreneurship and Innovation. Amongst others, Mr. Blaak has held non-executive directorships in FlexGen Holding B.V., to-BBB Holding B.V. and Centocor B.V. Mr. Blaak holds an MSc in Physics and Business Economics from the Free University of Amsterdam and followed the Advanced Management Program of the Harvard Business School (AMP ‘81).

Aad de Winter

Mr. Aad de Winter has been Member of the Board of Supervisory Directors at Pharming Group NV since April 15, 2009. He has financial experience. He started his career at AMRO Bank in 1980. He worked in the areas of capital markets, investment banking and institutional investor relationship management. In 1990, Mr. de Winter became senior Advisor Corporate and Institutional Finance at NIBC (formerly De Nationale Investerings Bank). As of 1998, Mr. De Winter was at NYSE Euronext, Amsterdam responsible for advising and admitting companies to the stock exchange in Amsterdam as Director Listing & Issuer Relations. As of January 2009, Mr. de Winter is an Associate Partner of First Dutch Capital, Amsterdam and until 2014 a member of the China and India working group at the Holland Financial Centre which, inter alia, focused on attracting Chinese and Indian companies to a (cross) listing on the Euronext Amsterdam. He is also an Associate Partner at Nederlandsche Participatie Exchange (NPEX). Mr. de Winter has more than three decades of experience in assisting companies with stock exchange listings for various capital markets instruments. He holds a law degree from Erasmus University, Rotterdam, specializing in corporate law. He is Chairman of the Company's Audit Committee and Member of the Corporate Governance Committee.

Jan Egberts

Mr. Jan Egberts has served as Member of the Board of Supervisory Directors of Pharming Group NV since April 30, 2015. He is Member of the Company’s Audit Committee and Corporate Governance Committee. He has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as Chief Executive Officer at Agendia Inc., a molecular diagnostics company. Prior to this, Mr. Egberts was Chief Executive Officer of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. in 2013. Mr. Egberts also served as a senior healthcare advisor for 3i Group plc, a private equity firm and as President, Chairman and Chief Executive Officer of NovaDel Pharmaceuticals Inc., where he developed a portfolio of pre-clinical and clinical compounds, gaining FDA approval for two compounds. In addition, Mr. Egberts has held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Molnlycke Health Care. Mr. Egberts graduated from Erasmus University Medical School in the Netherlands and he obtained his MBA from Stanford after which he worked as a management consultant for McKinsey & Co. Mr. Egberts continues to serve on the supervisory board of CHDR (Center for Human Drug Research) and Implanet SA.

Jonh Ward

Mr. J. Barrie (Barrie) Ward has been Member of the Board of Supervisory Directors at Pharming Group NV since May 23, 2007. He has experience in managing and financing biopharmaceutical companies. He has held senior management positions in the UK, USA and Singapore at several pharmaceutical and biotechnology companies, including Glaxo Group Research Ltd, Virus Research Institute Inc, Avant Immunotherapeutics Inc and KuDOS Pharmaceuticals Ltd. His most recent position was CEO of KuDOS Pharmaceuticals Ltd, which was sold to Astra-Zeneca in 2006. Mr. Ward holds a PhD in microbiology from the University of Bath, UK. He is Chairman of the Company's Corporate Governance and Remuneration Committees.

Basic Compensation

Name Fiscal Year Total

Paul Sekhri

45,000

Sijmen de Vries

1,789,000

Juergen Ernst

58,000

Robin Wright

53,000

Bruno Giannetti

1,121,000

Anne-Marie de Groot

--

Jaap Blaak

66,000

Aad de Winter

56,000

Jan Egberts

45,000

Jonh Ward

56,000
As Of  30 Dec 2015